GlobeNewswire
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
📊
AI Sentiment
Positive
7/10
- Home
- MOLN
as of 12-16-2025 10:49am EST
$4.04
$0.19
-4.49%
Stocks Nasdaq
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Chart Type:
Time Range:
| Founded: | 2004 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 157.8M | IPO Year: | 2021 |
| Target Price: | $3.75 | AVG Volume (30 days): | 3.5K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.36 - $5.91 | Next Earning Date: | 10-30-2025 |
| Revenue: | N/A | Revenue Growth: | -29.38% |
| Revenue Growth (this year): | -79.48% | Revenue Growth (next year): | 1000.00% |
AI-Powered MOLN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 63.85%
63.85%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Molecular Partners AG News
MOLN Breaking Stock News: Dive into MOLN Ticker-Specific Updates for Smart Investing
24/7 Wall St.
Social Security COLAs Don’t Cut It. Here’s How An Annuity Can Fill That Gap
📉
AI Sentiment
Negative
3/10
24/7 Wall St.
SOXL’s $13.6 Billion Fund Faces Rebalancing Drag as Memory Cycle Enters Critical Phase
📈
AI Sentiment
Highly Positive
8/10
Euronews
China’s economy loses momentum amid spending and investment slump
📉
AI Sentiment
Negative
2/10
Offshore Technology
Falcon completes SS2-1H well stimulation in Beetaloo sub-basin
📈
AI Sentiment
Highly Positive
8/10
24/7 Wall St.
Much Better Than a CD: 3 ETFs Paying Over 6% That You Can Sell Anytime
📈
AI Sentiment
Highly Positive
8/10
decrypt
Terra Founder Do Kwon May Face South Korean Trial Despite 15-Year US Prison Sentence
⚠️
AI Sentiment
Highly Negative
1/10
Compare MOLN vs Leading Stocks
See how MOLN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MOLN Molecular Partners AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.